Press Centre
Press Releases
Phynova Announces Start of Clinical Study in Post Operative Ileus in China
21 September 2009
Phynova Group Ltd
("Phynova" or the "Company")
PHYNOVA ANNOUNCES START OF CLINICAL STUDY IN POST OPERATIVE ILEUS IN CHINA
Phynova announces today that its JV partner in China, Botanic Century, has now enrolled its first patients in a Phase IIa safety and dose ranging clinical study of its candidate drug ´TQS´ in post operative ileus (the temporary stasis of the bowel that often follows abdominal surgery).
Post operative ileus is a clinical problem recognised world wide and various estimates put the cost to the US health system alone at around $1 billion per year, mainly representing the increased time patients spend in hospital after surgery and before they can be sent home.
Phynova has the rights to this drug (´PYN9´) outside China and is already promoting the opportunity to western pharmaceutical companies in anticipation of the clinical data being available in late 2009.
The clinical study is being carried out in three hospitals, the Beijing People´s Hospital, the Beijing Friendship Hospital and Tianjin City Hospital.
For further information, please contact:
Phynova Group Ltd
Robert Miller (CEO) +44 (0) 1993 880700
Tony Mills (CCO)
Notes to Editors:
About Phynova
Phynova is a UK company developing new prescription pharmaceuticals derived from plants used in Chinese medicines, functional ingredients for the cosmetic, food and supplement industries and OTC products capable of being registered under the Traditional Herbal Medicinal Products scheme.
For further information please visit www.phynova.com.
21/09/2009
<< Back | See all current Press releses